These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 36476495)

  • 1. Yap governs a lineage-specific neuregulin1 pathway-driven adaptive resistance to RAF kinase inhibitors.
    Garcia-Rendueles MER; Krishnamoorthy G; Saqcena M; Acuña-Ruiz A; Revilla G; de Stanchina E; Knauf JA; Lester R; Xu B; Ghossein RA; Fagin JA
    Mol Cancer; 2022 Dec; 21(1):213. PubMed ID: 36476495
    [TBL] [Abstract][Full Text] [Related]  

  • 2. NF2 Loss Promotes Oncogenic RAS-Induced Thyroid Cancers via YAP-Dependent Transactivation of RAS Proteins and Sensitizes Them to MEK Inhibition.
    Garcia-Rendueles ME; Ricarte-Filho JC; Untch BR; Landa I; Knauf JA; Voza F; Smith VE; Ganly I; Taylor BS; Persaud Y; Oler G; Fang Y; Jhanwar SC; Viale A; Heguy A; Huberman KH; Giancotti F; Ghossein R; Fagin JA
    Cancer Discov; 2015 Nov; 5(11):1178-93. PubMed ID: 26359368
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Small-molecule MAPK inhibitors restore radioiodine incorporation in mouse thyroid cancers with conditional BRAF activation.
    Chakravarty D; Santos E; Ryder M; Knauf JA; Liao XH; West BL; Bollag G; Kolesnick R; Thin TH; Rosen N; Zanzonico P; Larson SM; Refetoff S; Ghossein R; Fagin JA
    J Clin Invest; 2011 Dec; 121(12):4700-11. PubMed ID: 22105174
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Yes-activated protein promotes primary resistance of
    Su M; Zhan L; Zhang Y; Zhang J
    J Gastrointest Oncol; 2021 Jun; 12(3):953-963. PubMed ID: 34295548
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pin1 inhibitor API-1 sensitizes BRAF-mutant thyroid cancers to BRAF inhibitors by attenuating HER3-mediated feedback activation of MAPK/ERK and PI3K/AKT pathways.
    Dang H; Sui M; He Q; Xie J; Liu Y; Hou P; Ji M
    Int J Biol Macromol; 2023 Sep; 248():125867. PubMed ID: 37473892
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The MEK1/2 Inhibitor AZD6244 Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Song H; Zhang J; Ning L; Zhang H; Chen D; Jiao X; Zhang K
    Med Sci Monit; 2018 May; 24():3002-3010. PubMed ID: 29737325
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term vemurafenib treatment drives inhibitor resistance through a spontaneous KRAS G12D mutation in a BRAF V600E papillary thyroid carcinoma model.
    Danysh BP; Rieger EY; Sinha DK; Evers CV; Cote GJ; Cabanillas ME; Hofmann MC
    Oncotarget; 2016 May; 7(21):30907-23. PubMed ID: 27127178
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Disulfiram/Cu Kills and Sensitizes
    Xie J; Liu J; Zhao M; Li X; Wang Y; Zhao Y; Cao H; Ji M; Chen M; Hou P
    Int J Mol Sci; 2023 Feb; 24(4):. PubMed ID: 36834830
    [No Abstract]   [Full Text] [Related]  

  • 9. Inhibitors of Raf kinase activity block growth of thyroid cancer cells with RET/PTC or BRAF mutations in vitro and in vivo.
    Ouyang B; Knauf JA; Smith EP; Zhang L; Ramsey T; Yusuff N; Batt D; Fagin JA
    Clin Cancer Res; 2006 Mar; 12(6):1785-93. PubMed ID: 16551863
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Fine-Tuning Lipid Metabolism by Targeting Mitochondria-Associated Acetyl-CoA-Carboxylase 2 in
    Valvo V; Iesato A; Kavanagh TR; Priolo C; Zsengeller Z; Pontecorvi A; Stillman IE; Burke SD; Liu X; Nucera C
    Thyroid; 2021 Sep; 31(9):1335-1358. PubMed ID: 33107403
    [No Abstract]   [Full Text] [Related]  

  • 11. Inhibiting BRAF Oncogene-Mediated Radioresistance Effectively Radiosensitizes BRAF
    Robb R; Yang L; Shen C; Wolfe AR; Webb A; Zhang X; Vedaie M; Saji M; Jhiang S; Ringel MD; Williams TM
    Clin Cancer Res; 2019 Aug; 25(15):4749-4760. PubMed ID: 31097454
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mitochondrial localization and regulation of BRAFV600E in thyroid cancer: a clinically used RAF inhibitor is unable to block the mitochondrial activities of BRAFV600E.
    Lee MH; Lee SE; Kim DW; Ryu MJ; Kim SJ; Kim SJ; Kim YK; Park JH; Kweon GR; Kim JM; Lee JU; De Falco V; Jo YS; Shong M
    J Clin Endocrinol Metab; 2011 Jan; 96(1):E19-30. PubMed ID: 20926530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EGFR-mediated re-activation of MAPK signaling contributes to insensitivity of BRAF mutant colorectal cancers to RAF inhibition with vemurafenib.
    Corcoran RB; Ebi H; Turke AB; Coffee EM; Nishino M; Cogdill AP; Brown RD; Della Pelle P; Dias-Santagata D; Hung KE; Flaherty KT; Piris A; Wargo JA; Settleman J; Mino-Kenudson M; Engelman JA
    Cancer Discov; 2012 Mar; 2(3):227-35. PubMed ID: 22448344
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Actin remodeling confers BRAF inhibitor resistance to melanoma cells through YAP/TAZ activation.
    Kim MH; Kim J; Hong H; Lee SH; Lee JK; Jung E; Kim J
    EMBO J; 2016 Mar; 35(5):462-78. PubMed ID: 26668268
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relief of feedback inhibition of HER3 transcription by RAF and MEK inhibitors attenuates their antitumor effects in BRAF-mutant thyroid carcinomas.
    Montero-Conde C; Ruiz-Llorente S; Dominguez JM; Knauf JA; Viale A; Sherman EJ; Ryder M; Ghossein RA; Rosen N; Fagin JA
    Cancer Discov; 2013 May; 3(5):520-33. PubMed ID: 23365119
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
    Roskoski R
    Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting Autophagy Sensitizes BRAF-Mutant Thyroid Cancer to Vemurafenib.
    Wang W; Kang H; Zhao Y; Min I; Wyrwas B; Moore M; Teng L; Zarnegar R; Jiang X; Fahey TJ
    J Clin Endocrinol Metab; 2017 Feb; 102(2):634-643. PubMed ID: 27754804
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Upregulation of TRIB2 by Wnt/β-catenin activation in BRAF
    Wang N; Wen J; Ren W; Wu Y; Deng C
    Cancer Chemother Pharmacol; 2021 Jul; 88(1):155-164. PubMed ID: 33860836
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Metastasis-associated MCL1 and P16 copy number alterations dictate resistance to vemurafenib in a BRAFV600E patient-derived papillary thyroid carcinoma preclinical model.
    Duquette M; Sadow PM; Husain A; Sims JN; Antonello ZA; Fischer AH; Song C; Castellanos-Rizaldos E; Makrigiorgos GM; Kurebayashi J; Nose V; Van Hummelen P; Bronson RT; Vinco M; Giordano TJ; Dias-Santagata D; Pandolfi PP; Nucera C
    Oncotarget; 2015 Dec; 6(40):42445-67. PubMed ID: 26636651
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720.
    Kamata T; Dankort D; Kang J; Giblett S; Pritchard CA; McMahon M; Leavitt AD
    Mol Cancer Res; 2013 Dec; 11(12):1530-41. PubMed ID: 24152792
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.